In 2023, approximately 69,000 Americans contracted hepatitis C (HCV), a figure that represents a staggering doubling of infection rates from the mid-2010s. This surge occurs against the backdrop of a medical success story: for over a decade, HCV has been considered a curable condition through a straightforward, eight- to 12-week course of direct-acting antivirals (DAAs). Yet, as the medical community celebrates clinical milestones, the gap between controlled trial efficacy and real-world public health outcomes remains a critical hurdle in the global mission to eradicate the virus.
AbbVie’s Maviret (glecaprevir/pibrentasvir) stands at the center of this discourse. Following its regulatory success as a treatment for chronic infection, the drug secured a landmark label expansion in the United States in June 2025 and in the European Union in June 2026, marking it as the first antiviral specifically cleared for the treatment of acute hepatitis C. While clinical trials boast a near-perfect cure rate, experts warn that the true measure of success lies not in the lab, but in the ability to reach the most vulnerable populations.
A Chronology of Clinical Progress
The evolution of hepatitis C treatment is a narrative of rapid acceleration. Before the current generation of DAAs, the standard of care—alpha interferon injections—was grueling for patients and largely ineffective, yielding viral eradication rates of only about 10%. Since 1991, the landscape has shifted from those early, low-success regimens to the highly potent direct-acting antivirals used today.
- 2017: The European Union and the United States FDA grant approval for Maviret to treat chronic HCV across all major genotypes (1-6) in as little as eight weeks.
- June 2025: The FDA approves an expanded indication for Maviret, making it the first and only treatment specifically approved for acute hepatitis C infections in the U.S.
- June 2026: The European Commission follows suit, granting extended approval for the drug to treat acute HCV, signaling a shift in policy that favors immediate intervention over "watchful waiting."
This regulatory evolution is designed to bypass the traditional administrative bottleneck where patients were forced to wait for their infection to progress to a "chronic" state before receiving insurance-approved treatment. By authorizing early intervention, regulators are finally aligning drug labels with modern clinical guidelines, which emphasize that the most effective time to treat is immediately upon diagnosis.
Supporting Data: Efficacy and the Reality of Reinfection
The clinical evidence supporting Maviret is robust. In the pivotal Phase 3 trials that led to the drug’s expanded indication, the results were definitive. Among the intention-to-treat population, the sustained virologic response (SVR) rate reached 96.2% at 12 weeks. When excluding non-virologic failures, the success rate climbed to a perfect 100%. Perhaps most significantly, the trial reported zero on-treatment virologic failures and no post-treatment relapses.
However, these trials also shed light on the complex reality of HCV transmission. Approximately 18% of the trial participants were being treated for at least their second HCV infection, and nearly 40% of those individuals had a history of two or more prior infections. In some extreme cases, participants had contracted the virus six times.
Crucially, the data suggests that prior exposure does not diminish the efficacy of the drug. "The study found that a history of prior HCV infection did not appear to affect the SVR," noted Dr. Ivan Gentile, an infectious disease specialist at the University of Naples Federico II and co-author of the trial. "These findings suggest that neither prior infection nor previous exposure to the same regimen compromised the virologic response."
This resilience of the drug is vital because it challenges the stigma surrounding reinfection. Rather than viewing patients with repeated infections as "non-compliant," medical experts are beginning to see them as the primary targets for aggressive, iterative public health interventions.
Official Responses and Strategic Perspectives
The medical community has largely lauded the move toward early treatment, yet there is a call for a more holistic approach to the HCV crisis. John Ward, director of the Coalition for Global Hepatitis Elimination, emphasized the potential for total eradication in an AbbVie press release: "If treated early with safe and effective therapies, providers can cure virtually all patients with hepatitis C before it escalates to chronic disease."
However, Dr. Gentile, reflecting on the trial’s implications, warned that medical treatment alone is insufficient. "Antiviral treatment does not modify the underlying exposure," he stated. "Repeated treatment must therefore be integrated into a broader prevention strategy, including harm-reduction services, access to sterile injecting equipment, treatment for substance-use disorders when appropriate, sexual-health interventions, regular HCV RNA testing, and rapid retreatment following reinfection."
This perspective shifts the goalposts. The objective is no longer just "treating the virus" but "managing the patient’s environment." For individuals with higher risks—such as those who inject drugs or those with ongoing sexual exposure risks—the reinfection rate can be as high as 5.9 per 100 person-years, significantly higher than the general population rate of 1.27.
Implications for Public Health and Future Research
While the efficacy of Maviret is beyond reproach, the "real-world" effectiveness remains an open question. Dr. Gentile highlighted a notable limitation in the current trial data: the patient demographics. Only 14.3% of the participants in the Phase 3 trial were classified as people who currently or recently injected drugs. Furthermore, nearly half of the participants were HIV-positive, but all were already on antiretroviral therapy and, by extension, well-integrated into the formal healthcare system.
This suggests that the trial results may not fully translate to the populations that are hardest to reach—those who are homeless, incarcerated, or lack a stable connection to primary care. The "dropout rate" in the trial was low, but that is a luxury rarely afforded to clinicians working in community clinics or needle-exchange programs.
The Path Forward
To bridge the gap between clinical success and public health impact, researchers and policymakers must prioritize:
- Administrative Reform: The EU’s recent approval of the acute indication is a major step in removing the barrier of "waiting for chronicity." Similar systemic changes are needed across global healthcare networks to ensure that diagnosis equals immediate access to medication.
- Expanded Clinical Research: Future studies must specifically target populations that are currently disconnected from the healthcare system. Data collection must go beyond SVR rates and include metrics such as time-to-treatment-initiation and the proportion of patients who complete their regimen in unstable environments.
- Integrated Care Models: As Dr. Gentile noted, reinfection should be viewed as a signal that the patient needs more support, not a reason to withhold further treatment. Integrating HCV treatment into harm-reduction services is the only way to ensure that the 96% cure rate observed in trials becomes a reality for the general population.
In conclusion, while Maviret represents a triumph of pharmaceutical science, the battle against hepatitis C is far from won. The drug is a potent tool, but it is only as effective as the system that delivers it. If the medical community can move beyond the clinical setting and into the community, there is a tangible path to eliminating a disease that has plagued humanity for decades. The focus must now shift from the laboratory to the front lines of care, where the real, and much more complicated, work begins.
About the Author
